Top

Published in:

Open Access 01-05-2020 | Amphotericin B | Original Article

Invasive mucormycosis during treatment for acute lymphoblastic leukaemia—successful management of two life-threatening diseases

Authors: Andreas Trobisch, R. Marterer, G. Gorkiewicz, S. Flaschberger, H. Lackner, M. Seidel, D. Sperl, A. Karastaneva, B. Kohlmaier, M. Egger, C. Urban, M. Benesch, V. Strenger

Published in: Supportive Care in Cancer | Issue 5/2020

Abstract

A 5-year-old patient treated for acute lymphoblastic leukaemia (ALL) developed proven pulmonary invasive fungal disease (IFD) due to Actinomucor elegans. While completing ALL treatment according to AIEOP ALL protocol 2009 for further 15 months, antifungal treatment with liposomal amphotericin B and intermittent additional posaconazole was continued until immune reconstitution 7 months after the end of ALL treatment. Repeated imaging guided treatment decisions. Twenty-six and 19 months after the end of ALL treatment and antifungal treatment, respectively, the patient is still in the first complete remission and shows no signs of active invasive fungal disease (IFD).

Lamoth F, Calandra T (2017) Early diagnosis of invasive mould infections and disease. J Antimicrob Chemother 72(suppl_1):i19–i28CrossRef

Dorin J, D’Aveni M, Debourgogne A, Cuenin M, Guillaso M, Rivier A, Gallet P, Lecoanet G, Machouart M (2017) Update on Actinomucor elegans, a mucormycete infrequently detected in human specimens: how combined microbiological tools contribute efficiently to a more accurate medical care. Int J Med Microbiol 307(8):435–442CrossRef

Roden MM et al (2005) Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 41(5):634–653CrossRef

Katragkou A, Walsh TJ, Roilides E (2014) Why is mucormycosis more difficult to cure than more common mycoses? Clin Microbiol Infect 20(Suppl 6):74–81CrossRef

Skiada A, Pagano L, and Groll AEA 2010 Zygomycosis in Europe - analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) working group on zygomycosis between 2005 and 2007. Clin Microbiol Infect

Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M, Barrett J, Anaissie EJ (2001) Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 45(12):3487–3496CrossRef

Dannaoui E (2002) In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 51(1):45–52CrossRef

Hoenigl M, Strenger V, Buzina W, Valentin T, Koidl C, Wolfler A, Seeber K, Valentin A, Strohmeier AT, Zollner-Schwetz I, Raggam RB, Urban C, Lass-Florl C, Linkesch W, Krause R (2012) European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies. J Antimicrob Chemother 67(8):2029–2033CrossRef

De Pauw B et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46(12):1813–1821CrossRef

10.

Gomes MZ, Lewis RE, Kontoyiannis DP (2011) Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev 24(2):411–445CrossRef

11.

Mahmud A et al (2012) Actinomucor elegans as an emerging cause of mucormycosis. J Clin Microbiol 50(3):1092–1095CrossRef

12.

Davel G, Featherston P, Fernandez A, Abrantes R, Canteros C, Rodero L, Sztern C, Perrotta D (2001) Maxillary sinusitis caused by Actinomucor elegans. J Clin Microbiol 39(2):740–742CrossRef

13.

Khan ZU, Ahmad S, Mokaddas E, Chandy R, Cano J, Guarro J (2008) Actinomucor elegans var. kuwaitiensis isolated from the wound of a diabetic patient. Antonie Van Leeuwenhoek 94(3):343–352CrossRef

14.

Tully CC, Romanelli AM, Sutton DA, Wickes BL, Hospenthal DR (2009) Fatal Actinomucor elegans var. kuwaitiensis infection following combat trauma. J Clin Microbiol 47(10):3394–3399CrossRef

15.

Groll AH, Castagnola E, Cesaro S, Dalle JH, Engelhard D, Hope W, Roilides E, Styczynski J, Warris A, Lehrnbecher T (2014) Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 15(8):e327–e340CrossRef

16.

Dornbusch HJ, Strenger V, Kerbl R, Lackner H, Schwinger W, Sovinz P, Urban C (2005) Procalcitonin--a marker of invasive fungal infection? Support Care Cancer 13(5):343–346CrossRef

17.

Egger M et al (2018) False positive serum levels of (1-3)—ß-D-glucan after infusion of intravenous immunoglobulins and time to normalisation. J Inf Secur 76(2):206–210

18.

Strenger V, Farowski F, Müller C, Hofer N, Dornbusch HJ, Sperl D, Lackner H, Benesch M, Urban C (2017) Low penetration of caspofungin into cerebrospinal fluid following intravenous administration of standard doses. Int J Antimicrob Agents 50(2):272–275CrossRef

19.

Strenger V, Meinitzer A, Donnerer J, Hofer N, Dornbusch HJ, Wanz U, Seidel MG, Sperl D, Lackner H, Schwinger W, Sovinz P, Benesch M, Urban C (2014) Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B. J Antimicrob Chemother 69(9):2522–2526CrossRef

20.

Spellberg B, Ibrahim AS (2010) Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep 12(6):423–429CrossRef

21.

Danion F, Aguilar C, Catherinot E, Alanio A, DeWolf S, Lortholary O, Lanternier F (2015) Mucormycosis: new developments into a persistently devastating infection. Semin Respir Crit Care Med 36(5):692–705CrossRef

22.

Skiada A, Lanternier F, Groll AH, Pagano L, Zimmerli S, Herbrecht R, Lortholary O, Petrikkos GL, on behalf of the third European Conference on Infections in Leukemia* (2013) Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 98(4):492–504CrossRef

23.

Ellis M (2008) New dosing strategies for liposomal amphotericin B in high-risk patients. Clin Microbiol Infect 14(Suppl 4):55–64CrossRef

24.

Bochennek K, Tramsen L (2011) Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients. Clin Microbiol Infect 17:1868–1874CrossRef

25.

Hot A, Maunoury C, Poiree S, Lanternier F, Viard JP, Loulergue P, Coignard H, Bougnoux ME, Suarez F, Rubio MT, Mahlaoui N, Dupont B, Lecuit M, Faraggi M, Lortholary O (2011) Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect 17(3):409–417CrossRef

26.

Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, Gadner H, Odenwald E, Riehm H (2000) Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 14(12):2205–2222CrossRef

Title: Invasive mucormycosis during treatment for acute lymphoblastic leukaemia—successful management of two life-threatening diseases
Authors: Andreas Trobisch
R. Marterer
G. Gorkiewicz
S. Flaschberger
H. Lackner
M. Seidel
D. Sperl
A. Karastaneva
B. Kohlmaier
M. Egger
C. Urban
M. Benesch
V. Strenger
Publication date: 01-05-2020
Publisher: Springer Berlin Heidelberg
Keywords: Amphotericin B
Acute Lymphoblastic Leukemia
Maintenance Therapy
Zygomycosis
Published in: Supportive Care in Cancer / Issue 5/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-019-04962-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2020

Distress screening and supportive care referrals used by telephone-based health services: a systematic review

The importance of physical function in patients with multiple myeloma for improving quality of life

Exploring the perspectives of patients about their care experience: identifying what patients perceive are important qualities in cancer care

Self-reported and objective taste and smell evaluation in treatment-naive solid tumour patients

Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines

Development of an evidence-based decision aid on complementary and alternative medicine (CAM) and pain for parents of children with cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer